GLP-1 RAs offer improved glycaemia, weight loss and cardiovascular benefits in those for whom they are recommended by the guidelines, so it is important that we facilitate their initiation and continuation in as many appropriate people as possible
It is important that you fully read the information given to you by your doctor and seek answers to any questions or concerns
This approach is typically recommended during the stable or recovery phase of AP and may provide supportive benefit, though it is not a substitute for core treatment strategies
it just requires some added context
Foundayo gives patients a new once daily pill option and expands Ro's comprehensive weight loss formulary NEW YORK, April 9, 2026 /PRNewswire/ -- Ro, the leading direct-to-patient healthcare company, today announced eligible patients can now access Foundayo (orforglipron) Eli Lilly Company's newest oral GLP-1 innovation on the Ro platform, adding to Ro's already comprehensive formulary of FDA-approved GLP-1s
Wegovy prescribing information
